Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Mieloma First Relpase Rd-base Triplet

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione IRCCS Policlinico San Matteo

Pavia, 27100, Italy

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice
Age ≥18 years
Written informed consent signed by the patient

Exclusion criteria

the patient's refusal to participate

Treatment and study plan

Primary outcomes

Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd))

Time frame: The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020

Sponsors and collaborators

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Other

Registry information

Important dates

Study start: 2021
Primary completion: 2024
Study completion: 2025
First posted: May 28, 2026
Registry last updated: May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed